Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.
Drugs · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
HumansAlzheimer DiseaseBiomarkersAmyloid beta-PeptidesApolipoprotein E4FemaleAdministration, OralMaleNeuroimagingCognitive Dysfunctiontau ProteinsMagnetic Resonance ImagingNeurofilament ProteinsAged
Come citare questo studio
John A Hey, Susan Abushakra, Aidan Power, David Watson, Anton Porsteinsson, Marwan Sabbagh, Emer MacSweeney, Sharon Cohen, Mercè Boada, P Murali Doraiswamy, Fanny M Elahi, Robert A Rissman, Earvin Liang, Susan Flint, Elitza Hristova, Patrick Kesslak, Rosalind McLaine, Adem Albayrak, Jean F Schaefer, Jeremy Y Yu, Luke Tolar, Martin Tolar. (2026). Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.. Drugs. DOI: 10.1007/s40265-026-02381-3
Consulta la pubblicazione originale ↗